Muscular LMNA-interacting protein (MLIP)

Muscular LMNA-interacting protein (MLIP) is a chromatin-binding protein highly expressed in heart, skeletal, and smooth muscle, regulated through alternative splicing with tissue-specific isoforms[1][2][3][4][5]. It was originally discovered for its interaction with A-type lamins (lamin A/C) at the nuclear envelope and is also able to bind chromatin, potentially functioning as a transcriptional co-factor[3][4]. MLIP is implicated in maintaining cardiac homeostasis and protecting against cardiac hypertrophy[4][5], plays a critical role in skeletal muscle differentiation, and may regulate myogenic differentiation by activating expression of myogenic regulatory factors such as MyoD and MyoG[3][2]. Pathogenic alterations in MLIP are associated with myopathies characterized by myalgia, elevated serum creatine kinase, and episodic rhabdomyolysis, and may contribute to intellectual developmental disorders[5]. There is currently no direct evidence that MLIP is a therapeutic drug target, nor are any drugs or clinical biomarkers established for it. MLIP is not a receptor, enzyme, transporter, or GPCR, but rather functions as a nuclear protein modulating transcriptional programs relevant to muscle and heart biology[3][4][5].

Other names

C6orf142CIPMGC18257Cardiac ISL1-interacting proteinMuscle-enriched A-type lamin-interacting proteinmuscle-enriched A-type lamin interacting proteincardiac Isl1-interacting proteinMMCKRMLIP intronic transcript 1MLIP-IT1LOC101927189